Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
CJC-1295 vs. Ipamorelin vs. Tesamorelin: The Growth Hormone Axis Group, Compared
For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Tesamorelin is FDA-approved as a prescription drug (Egrifta) for a specific indication; CJC-1295 and Ipamorelin are not approved by Health Canada or the FDA for any use, and research-grade tesamorelin used outside its approved indication falls into that same unapproved category.
Last updated: July 2026
Three compounds, one shared goal — stimulating the body’s own growth hormone release rather than introducing synthetic GH directly — and three genuinely different evidence stories sitting underneath that shared goal. This is the category where the gap between “what’s commonly used” and “what’s actually been proven in humans” is widest of anywhere in this guide series, and understanding that gap clearly is more valuable here than in almost any other comparison we cover.
At a Glance
| CJC-1295 (no DAC) | Ipamorelin | Tesamorelin | |
|---|---|---|---|
| Receptor target | GHRH receptor | GHSR (ghrelin) receptor | GHRH receptor |
| Developer | ConjuChem Inc. | Novo Nordisk | Theratechnologies |
| Furthest development stage | Phase 2 (DAC version, HIV lipodystrophy) — discontinued for commercial reasons | Phase 2 (postoperative ileus) — discontinued after the trial failed its primary endpoint | Phase 3 — completed, approved |
| Completed human efficacy trial for its actual current use case | None | None (its one trial tested an unrelated indication) | Yes — the trials that led to its approval directly measured its approved use |
| Regulatory status (2026) | Not approved; removed from FDA Category 2, not placed in Category 1, pending PCAC review | Not approved; same regulatory gap as CJC-1295 | FDA-approved (Egrifta), actively marketed, cGMP-manufactured |
| Named safety signal in FDA documentation | Yes — cardiac adverse events, pituitary cell DNA damage findings cited in 2023 Category 2 classification | No specific named signal; general “insufficient data” classification | Documented, quantified in trials (HbA1c elevation in ~5% of users) |
| Typical community role | GHRH half of the standard stacked protocol | GHSR half of the standard stacked protocol | Standalone, or paired with Ipamorelin, for visceral-fat-specific research |
The Mechanism: Two Pathways, One Target
All three compounds ultimately aim at the same cells — the somatotrophs, the growth-hormone-producing cells of the pituitary gland — but they arrive there through genuinely different receptor doors.
CJC-1295 and Tesamorelin both activate the GHRH receptor, the same receptor the body’s own growth hormone-releasing hormone binds to naturally. Both are, in that sense, more “faithful” analogs of an existing signal than Ipamorelin is.
Ipamorelin activates a completely separate receptor — GHSR, the ghrelin receptor, the same one the “hunger hormone” ghrelin binds to. This is a structurally and functionally distinct pathway, which is exactly why combining Ipamorelin with either CJC-1295 or Tesamorelin produces a larger GH pulse than either compound alone: two independent signals converging on the same cells amplify each other rather than simply adding up.
This mechanistic split — two GHRH-pathway compounds, one GHSR-pathway compound — is the reason the standard community combinations exist at all. It’s not an arbitrary pairing convention; it reflects real, complementary pharmacology.
The Evidence Gap: The Single Most Important Thing to Understand About This Category
Here’s the pattern that makes this comparison genuinely different from the GLP-1 trio or the regenerative compound group: in this category, the compound with the most human trial history isn’t necessarily the one most people are actually using, and the compound most people are actually using has evidence that doesn’t map cleanly onto how it’s actually used.
CJC-1295’s human data is real, but it’s for the wrong version. The 2006 Teichman trial — genuine, published, peer-reviewed Phase 1 data — studied CJC-1295 with DAC, at a single dose, measuring its extended pharmacokinetic profile. The version the overwhelming majority of current researchers actually use is the no-DAC version, administered daily, for its short, clean, pulsatile pattern — a meaningfully different formulation and use pattern than what that trial actually measured.
Ipamorelin’s human data is real, but it’s for an unrelated purpose, and it failed. Its only completed human efficacy trial tested whether its gastroprokinetic properties could speed gut recovery after bowel surgery. It did not test GH release, body composition, sleep, or recovery — the reasons people actually research this compound today — and the trial itself failed to meet its primary endpoint. This is arguably the most misunderstood fact in this entire category: a lot of casual material implies “ipamorelin has human trial support” without mentioning what that trial was actually testing.
Tesamorelin’s human data is real, and it directly measures its actual current use case. The Phase 3 program that led to its approval measured visceral fat reduction in the same population, at essentially the same dose, using the same fundamental drug that’s prescribed today. This is the one compound in the trio where “there’s clinical trial evidence for this” and “that evidence describes how the compound is actually being used” are the same statement.
None of this means CJC-1295 or Ipamorelin don’t work as commonly understood — the underlying receptor pharmacology for both is well-established and scientifically sound. It means the specific claim “this has been tested and shown to work in humans, for this purpose” is only fully true for one of the three compounds in this comparison.
Regulatory Status: A Genuinely Different Picture for Each
This category has the widest regulatory spread of anything covered in this guide series.
Tesamorelin is an active, FDA-approved, cGMP-manufactured pharmaceutical, most recently updated with a new formulation (Egrifta WR) in March 2025. It requires a prescription for its approved indication and is held to the same manufacturing oversight as any other biologic drug.
CJC-1295 and Ipamorelin share a nearly identical regulatory situation: both were placed into FDA Category 2 (restricting compounding pharmacy preparation) in 2023, and both were removed from that category in April 2026 without being placed into Category 1 — leaving both in an unclassified regulatory gap pending a Pharmacy Compounding Advisory Committee review in July 2026. Both were also specifically named in Health Canada’s April 2026 advisory on unauthorized injectable peptides.
One distinction worth knowing: CJC-1295’s 2023 Category 2 classification cited a specific, named safety concern — potential cardiac adverse events and FDA documentation referencing DNA damage findings in pituitary cells in nonclinical studies. Ipamorelin’s classification reflected the more general “insufficient safety data” rationale, without an equivalent named signal. That’s not the same as ipamorelin being cleared of concern — it reflects an absence of the kind of large-scale data that would let anyone make a stronger claim in either direction, for either compound.
Safety Profiles, Compared
Tesamorelin has the most quantified, trial-derived safety data of the three: joint pain, peripheral edema, and mild myalgia as the most common effects, and a specific, documented glucose-metabolism signal — about 5% of trial participants developed HbA1c levels in the diabetic range, versus 1% on placebo. No treatment-related deaths or serious cardiovascular events were reported across its trial program.
CJC-1295 and Ipamorelin both rely primarily on community-reported tolerability rather than large-scale trial safety data for their most common current use pattern. Commonly reported effects — water retention, mild joint discomfort, vivid dreams, and for Ipamorelin specifically, increased appetite (consistent with its ghrelin-receptor mechanism) — are broadly consistent with what you’d expect from amplified GH and IGF-1 signaling, but they aren’t backed by the kind of systematic, large-population safety monitoring that exists for an approved drug.
Across all three, the same theoretical concern applies: elevated IGF-1 signaling that supports muscle repair and body composition change could, in theory, also support the growth of an existing malignancy. This is why active cancer or a strong personal history of cancer is a caution — and for Tesamorelin specifically, a labeled contraindication — across the entire category.
Practical Considerations: How They’re Actually Used Together
CJC-1295 (no DAC) + Ipamorelin is by far the most common combination in current community research — GHRH-pathway and GHSR-pathway activation converging on the same pituitary cells, administered in the same bedtime, fasted injection. This pairing is common enough that pre-blended combination products exist specifically for it.
Tesamorelin + Ipamorelin is a documented, though less common, alternative — chosen by researchers who specifically want Tesamorelin’s more targeted, better-evidenced visceral fat profile as the GHRH-pathway half of the combination, rather than CJC-1295’s broader but less clinically validated activity.
Tesamorelin alone is the most defensible standalone choice of the three, precisely because it doesn’t need a GHSR-pathway partner to have trial-backed efficacy data behind it — CJC-1295 and Ipamorelin’s community reputations lean more heavily on the combination itself than on either compound’s individual, mismatched trial history.
Which One Actually Fits Your Research Objective?
Choose Tesamorelin if: you want the compound in this category with genuine regulatory approval, a completed Phase 3 program, and trial data that actually measures the outcome you’re researching — particularly if visceral fat reduction specifically is your objective. This is the most evidence-mature choice by a wide margin, though it comes with a prescription requirement for its approved use and less accessibility through community research channels.
Choose CJC-1295 + Ipamorelin if: broad GH-axis stimulation — body composition, recovery, sleep quality — is your objective, and you’re comfortable relying primarily on mechanistic plausibility and community-reported experience rather than direct human efficacy trials for that specific combination and use case. This is overwhelmingly the most common community approach, for reasons of cost and accessibility as much as evidence.
Be cautious of both if: you have any personal or family history of cancer, or an existing cardiac condition (particularly relevant for CJC-1295 specifically, given its named 2023 safety signal) — these are the situations where the gap between community popularity and rigorous safety data matters most.
Common Questions
Which of these three has actually been proven to work in humans for how people use it today? Only Tesamorelin, for its approved indication (visceral fat reduction in HIV-associated lipodystrophy). CJC-1295’s human data describes a different formulation than most current use; Ipamorelin’s human trial tested an unrelated indication and failed.
If CJC-1295 and Ipamorelin don’t have direct efficacy trials, does that mean they don’t work? Not necessarily — it means the specific human efficacy question hasn’t been directly and successfully tested for either compound’s current primary use case. The underlying receptor pharmacology is well-established; the leap from “the mechanism is real” to “the outcomes people want have been demonstrated in a human trial” hasn’t been completed for either compound.
Why is CJC-1295 + Ipamorelin so much more popular than Tesamorelin if Tesamorelin has better evidence? Largely cost and accessibility. Tesamorelin as an approved pharmaceutical requires a prescription and carries a different price point than research-vendor CJC-1295 and Ipamorelin, which remain far more accessible through community channels regardless of the evidence gap.
Is any one of these three definitively safer than the others? Tesamorelin has the most quantified safety data, simply because it went through a real trial program. That’s a different claim than “the others are unsafe” — it reflects a real, honest difference in how much is actually known, not a confirmed safety hierarchy.
Where to Go From Here
- CJC-1295: The Complete Guide
- Ipamorelin: The Complete Guide
- Tesamorelin: The Complete Guide
- CJC & Ipamorelin — the pre-blended combination product
- Our Canadian Regulatory Landscape Guide
- Our Reconstitution and Storage Guide
- Our Certificate of Analysis and Vendor Verification Guide
This guide reflects the evidence and regulatory information available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here outside its approved use to be used for human consumption.
AETHON LABS — Tested. Documented. Delivered.